Last reviewed · How we verify
VZV vaccine
At a glance
| Generic name | VZV vaccine |
|---|---|
| Also known as | zostavax |
| Sponsor | Baylor College of Medicine |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study to Learn About a Modified RNA Vaccine Against Shingles in Healthy Adults (PHASE1, PHASE2)
- Recombinant Herpes Zoster Vaccine for Prevention of Cardiovascular Events and Dementia (PHASE4)
- Safety and Immunogenicity of CVI-VZV-001 in Adults Aged 50 Years and Above (PHASE2)
- Is a Third Dose of MMRV Vaccine Beneficial for the Adult Population in Alberta?
- Immunogenicity and Safety of Varicella Vaccine, Live in Healthy Vietnamese Children Aged 1~12 Years: A Single-armed Bridging Clinical Trial (PHASE3)
- Second Dose of Varicella Vaccine in Healthy Children (PHASE3)
- Recombinant Herpes Zoster Vaccine in Patients With Autoimmune Rheumatic Diseases Under Immunomodulators (PHASE4)
- A Phase III Clinical Trial to Evaluate Long-Term Protective Efficacy of Recombinant Zoster Vaccine (CHO Cell) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- VZV vaccine CI brief — competitive landscape report
- VZV vaccine updates RSS · CI watch RSS
- Baylor College of Medicine portfolio CI